Novartis announced today that the European Medicines Agency's Human Medicines Committee has adopted a positive opinion recommending approval of Kesanting® for the treatment of polymyalgia rheumatica.

Zhitongcaijing · 3d ago
Novartis announced today that the European Medicines Agency's Human Medicines Committee has adopted a positive opinion recommending approval of Kesanting® for the treatment of polymyalgia rheumatica.